138 related articles for article (PubMed ID: 30062555)
21. A novel thyroid function index associated with opposite therapeutic outcomes in advanced hepatocellular carcinoma patients receiving chemotherapy or sorafenib.
Chu YD; Lin KH; Huang YH; Lin CC; Hung CF; Yeh TS; Lee WC; Yeh CT
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e341-e351. PubMed ID: 29785761
[TBL] [Abstract][Full Text] [Related]
22. Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma.
Williet N; Clavel L; Bourmaud A; Verot C; Bouarioua N; Roblin X; Merle P; Phelip JM
Dig Liver Dis; 2017 Sep; 49(9):1043-1049. PubMed ID: 28712860
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
[TBL] [Abstract][Full Text] [Related]
26. Predictive factors for sorafenib-induced hand-foot skin reaction using ordered logistic regression analysis.
Kanbayashi Y; Hosokawa T; Yasui K; Hongo F; Yamaguchi K; Moriguchi M; Miki T; Itoh Y
Am J Health Syst Pharm; 2016 Jan; 73(1):e18-23. PubMed ID: 26683674
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
28. Hand-foot syndrome due to sorafenib in hepatocellular carcinoma treated with vitamin E without dose modification; a preliminary clinical study.
Bozkurt Duman B; Kara B; Oguz Kara I; Demiryurek H; Aksungur E
J BUON; 2011; 16(4):759-64. PubMed ID: 22331734
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib.
da Fonseca LG; Marta GN; Braghiroli MIFM; Chagas AL; Carrilho FJ; Hoff PM; Sabbaga J
BMC Cancer; 2018 Dec; 18(1):1250. PubMed ID: 30545331
[TBL] [Abstract][Full Text] [Related]
30. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma.
Jeong SW; Jang JY; Lee JE; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Kim KH; Kim YJ
Asia Pac J Clin Oncol; 2012 Jun; 8(2):164-71. PubMed ID: 22524575
[TBL] [Abstract][Full Text] [Related]
31. Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.
Kaneko S; Ikeda K; Matsuzaki Y; Furuse J; Minami H; Okayama Y; Sunaya T; Ito Y; Inuyama L; Okita K
J Gastroenterol; 2016 Oct; 51(10):1011-21. PubMed ID: 26931117
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.
Hsu CH; Shen YC; Lin ZZ; Chen PJ; Shao YY; Ding YH; Hsu C; Cheng AL
J Hepatol; 2010 Jul; 53(1):126-31. PubMed ID: 20416968
[TBL] [Abstract][Full Text] [Related]
35. Facial nodulocystic eruption induced by sorafenib in a patient with hepatocellular carcinoma.
Duran-Vian C; Gómez-Fernández C; Navarro-Fernández I; Del Cura LR; Alonso-Buznego L; González-Vela MC; González-López MA
Indian J Dermatol Venereol Leprol; 2020; 86(4):409-411. PubMed ID: 32415051
[No Abstract] [Full Text] [Related]
36. Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study.
Hayashi T; Yamashita T; Terashima T; Suda T; Okada H; Asahina Y; Hayashi T; Hara Y; Nio K; Sunagozaka H; Takatori H; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S
BMC Cancer; 2017 Dec; 17(1):870. PubMed ID: 29258450
[TBL] [Abstract][Full Text] [Related]
37. [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
Turnes J; Díaz R; Hernandez-Guerra M; Gómez M; Castells L; Bustamante J; Espinosa MD; Fernández-Castroagudín J; Serrano T; Rendón P; Andrade R; Salgado M; Arenas J; Vergara M; Sala M; Polo BA; Granizo IM; Gonzálvez ML; Viudez A
Gastroenterol Hepatol; 2015 Apr; 38(4):263-73. PubMed ID: 25583146
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study.
Nada Y; Rashad N; Eissa M; Ghonaim A; Farag K; Saadawi I; Sheha A; El Gewaity M; Abdel-Rahman O
Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):99-107. PubMed ID: 29124987
[TBL] [Abstract][Full Text] [Related]
39. Relationship Between Adverse Events and Microbiomes in Advanced Hepatocellular Carcinoma Patients Treated With Sorafenib.
Yamamoto K; Kuzuya T; Honda T; Ito T; Ishizu Y; Nakamura M; Miyahara R; Kawashima H; Ishigami M; Fujishiro M
Anticancer Res; 2020 Feb; 40(2):665-676. PubMed ID: 32014907
[TBL] [Abstract][Full Text] [Related]
40. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
Edeline J; Blanc JF; Campillo-Gimenez B; Ma YT; King J; Faluyi O; Mathurin J; Ghazi S; Palmer DH; Meyer T
Eur J Cancer; 2017 Nov; 86():135-142. PubMed ID: 28987770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]